The earnings call presented a strong start to the fiscal year with record revenue growth, increased profitability, and a robust cash position. The company successfully expanded its international business and continued to lead in the Canadian market with its flagship product, FeraMAX. While there are challenges with certain products and external trade uncertainties, the overall performance and strategic initiatives demonstrate a positive outlook.

Company Guidance -

Q3 2025

In the Q1 2025 results presentation, BioSyent Inc. reported a revenue of just under $11 million, marking a 42% increase compared to the previous year and achieving a record quarter for the company. The EBITDA grew by 45% with a margin of 29% to revenue, while the net income after tax stood at over $2.3 million, representing 21% of revenue. The Canadian pharma business grew by 21% to just under $9.2 million, although the product Gelclair struggled in the market. The international pharmaceutical business saw a significant change, contributing over $1.5 million in the quarter due to the Tibelia acquisition. On a trailing 12-month basis ending March 31st, the earnings per share (EPS) increased from $0.62 to $0.67. The company also paid a dividend of $0.05 in March, an 11% increase from the previous year, and announced another $0.05 dividend for June. BioSyent maintained a strong balance sheet with just under $25 million in cash and no debt, resulting in a return on equity increase from 15% to 22%. The company generated $7 million in cash from operations over the trailing 12 months, returning $6.2 million to shareholders through share buybacks and dividends. The management emphasized their capital-light business model, focusing on revenue and profit growth, portfolio diversification, and maintaining an anti-dilutive approach to equity compensation.

Record Revenue Growth

Revenue reached just under $11 million for Q1 2025, representing a 42% increase versus the year-ago quarter.

Strong EBITDA and Profitability

EBITDA increased by 45% with a 29% margin to revenue. Net income after tax was over $2.3 million, 21% of revenue.

Canadian Pharma Business Growth

Canadian pharma business revenue increased by 21% year-over-year.

International Pharmaceutical Business Expansion

International pharmaceutical business generated over $1.5 million, a significant increase from no sales in the previous comparable period.

Tibelia Acquisition Impact

Tibelia acquisition added $800,000 in new revenue for the quarter.

Dividend Increase

Paid a dividend of $0.05 in March, representing an 11% increase versus the prior year.

FeraMAX Recognition

FeraMAX named the number one recommended oral iron supplement in Canada for the 10th consecutive year.

Consistent Profitability

Achieved 59 consecutive profitable quarters since Q2 2010.

Strong Balance Sheet

Maintained a cash position of just under $25 million with no debt.

Cash Return to Shareholders

Returned $6.2 million to shareholders through share buybacks and dividends.

Biosyent (TSE:RX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:RX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	- / -	0.2	―	―	―
Aug 21, 2025	2025 (Q2)	- / 0.18	0.13	38.46% (+0.05)	―	―
May 15, 2025	2025 (Q1)	- / 0.20	0.15	33.33% (+0.05)	―	―
Mar 13, 2025	2024 (Q4)	0.15 / 0.14	0.12	16.67% (+0.02)	―	―
Nov 20, 2024	2024 (Q3)	0.14 / 0.20	0.2	0.00% (0.00)	―	―
Aug 26, 2024	2024 (Q2)	0.13 / 0.13	0.12	8.33% (+0.01)	―	―
May 16, 2024	2024 (Q1)	0.08 / 0.15	0.1	50.00% (+0.05)	―	―
Mar 13, 2024	2023 (Q4)	0.17 / 0.12	0.09	33.33% (+0.03)	―	―
Nov 16, 2023	2023 (Q3)	0.10 / 0.20	0.116	72.41% (+0.08)	―	―
Aug 22, 2023	2023 (Q2)	0.12 / 0.12	0.1	20.00% (+0.02)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:RX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 21, 2025	C$11.59	C$12.01	+3.62%
May 15, 2025	C$10.72	C$11.70	+9.14%
Mar 13, 2025	C$10.75	C$11.15	+3.72%
Nov 20, 2024	C$10.77	C$11.16	+3.62%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Biosyent Inc (TSE:RX) report earnings?

Biosyent Inc (TSE:RX) is schdueled to report earning on Nov 13, 2025, TBA (Confirmed).

What is Biosyent Inc (TSE:RX) earnings time?

Biosyent Inc (TSE:RX) earnings time is at Nov 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:RX EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing